Reading CORZ? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CORZ free→Reading CORZ? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CORZ free→
NASDAQInformation TechnologySoftware - InfrastructureSnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality cannot be assessed since the company is unprofitable. Management's recent track record has been unsteady, with frequent changes. Risk is elevated, and the sector backdrop is a tailwind. Compared with sector peers, CORZ is below typical. Peer multiples imply a price about 88% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $28.22. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $28, CORZ's earnings are too small for P/E to mean much; on sales it trades at 22× p/s (5.1× the 4× p/s peer median). At a normal multiple the price implies ~129% near-term growth vs our ~-8% forecast. That gap is an optionality premium a financial-multiple model can't price — our $12 fair value covers only the as-is business, low confidence. Analysts: $20–$40. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 129% near-term growth, well above our forecast of about -8%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Flags: expensive valuation, a turbulent sector regime (Heating).
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Information Technology names rated weak grew net income 63% of the time over the next year (vs 62% for the rest of the cohort, n=2777).
Over the trailing year it converted -0.47x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates.
Not enough signal yet.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.04 → $-0.06 (-71.4% / 30d). 0 raised, 2 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 94% of analysts rate Buy.
2 PT revisions / 30d. Avg target 28.6% above current price.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$268.
How much price usually moves either way.
On a bad day, this stock has moved -$758.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,074.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If revenue growth drops, it shows a weaker position in a slowing sector.
Confirms:Core Scientific's revenue growth falls below the sector median growth rate.
Disproves:Core Scientific maintains or improves its revenue growth above the median.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CORZ yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 26, 2026, the Company announced the appointment of Steve M. Smith, as a member of the Board and the Nominating and Corporate Governance Committee of the Board, effective immediately. Mr. Smith, age 70, has been Chief Executive Officer and a member of the Board of Zayo, a global internet network provider since October 2020. From 2007 until 20…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
$20.00 – $40.00 (median $30.00) · 9 analysts · as of 2026-06-12
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Systems Software.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CORZ Core Scientific, Inc. | Below typical Show detailsSector percentile: 14 of 100 | expensive | elevated |
MSFT Microsoft | Above typical Show detailsSector percentile: 83 of 100 | full | moderate |
PANW Palo Alto Networks | Typical Show detailsSector percentile: 43 of 100 | expensive | moderate |
CRWD CrowdStrike | Typical Show detailsSector percentile: 31 of 100 | expensive | moderate |
FTNT Fortinet | Above typical Show detailsSector percentile: 91 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLK
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management is prioritizing capital allocation strategies, including debt management and share buybacks.
Stated in 3 of last 3 quarters. Core Scientific announced a $3.3 billion offering of Senior Secured Notes in 2026-Q1, indicating a focus on capital allocation and debt management. Despite this, the company reported a net income loss of $347.2 million in 2026-Q1, showing limited progress in improving financial stability.
“Announced a $3.3 billion offering of Senior Secured Notes.”
“Entered into a loan facility Credit Agreement.”
“Focused on capital allocation and debt management.”
Management aims to improve operational efficiency to drive profitability.
Stated in 2 of last 2 quarters. Despite management's focus on enhancing operational efficiency, the company reported an operating income loss of $310.4 million in 2026-Q1, compared to a loss of $117.5 million in 2025-Q4, indicating limited progress in achieving this priority.
“Emphasized the need to enhance operational efficiency.”
Management is committed to completing strategic acquisitions to expand market presence.
Newly stated in 2026-Q1. Core Scientific completed an acquisition agreement on May 5, 2026, indicating a strategic move to expand market presence. However, the financials for 2026-Q1 show a net income loss of $347.2 million, suggesting that the acquisition's impact on profitability is yet to be realized.
“Completed an acquisition agreement on May 5, 2026.”
is incorporated herein by reference. The information in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Entry into a Material Definitive Agreement. On May 5, 2026, Core Scientific, Inc., a Delaware corporation (the “Company”), entered into an agreement and plan of merger (the “Merger Agreement”) with Polar Merger Sub, LLC, a Nevada limited liability company and wholly owned subsidiary of the Company (“Merger Sub”), Polaris DS LLC, a Nevada limited liability company (the “Target”), Top Access Enterprises Limited, a company organized under the laws of Hong Kong and sole owner of the Target (“Sell…
Entry into a Material Definitive Agreement. On May 6, 2026, Core Scientific Finance I LLC (the “Issuer”), a wholly-owned indirect subsidiary of Core Scientific, Inc. (“Core Scientific”), completed its previously announced private offering (the “Offering”) of $3.3 billion aggregate principal amount of its 7.750% Senior Secured Notes due 2031 (the “Notes”). The Notes were sold under a purchase agreement, dated as of April 22, 2026, entered into by and among the Issuer, the subsidiary guarantors…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 30, 2026, the Board of Directors of Core Scientific, Inc. (the “Company”) appointed Jorge Ray as the Company’s Principal Accounting Officer, effective May 7, 2026. Mr. Ray, age 43, currently serves as Chief Accounting Officer of the Company and has held this position since March 2026. Prior to joining the Company, Mr. Ray served as Corpora…
“Focused on improving operational efficiency.”